Pharma IP – Protecting the Next Generation of Therapies

The Boardroom met to discuss the changing landscape of IP litigation in the European pharmaceutical market. There were a number of technical updates and explanations regarding second medical use, and a lot of detailed information on the manufacturing waiver and associated transition period.

The Boardroom benefited from the expert advice of the moderators: Mari Korsten and Jaap Mannaerts from NLO, and Judith Krens from Taylor Wessing. All of the participants found the clear guidance and direction extremely useful.

There was also discussion comparing litigation in different jurisdictions and analysis of the impact of Brexit. In many matters including SPC disclosure, and the divergence of UK courts from the rest of Europe, it was agreed that more time, and more cases would be needed to have very clear understanding of practices.